Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Public ClinicalTrials.gov record NCT00420212. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.
Study identification
- NCT ID
- NCT00420212
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,234 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Feb 2011 (Actual)
- Completion
- Feb 2011 (Actual)
- Last update posted
- Jan 26, 2015
2007 – 2011
United States locations
- U.S. sites
- 39
- U.S. states
- 25
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | San Francisco | California | — | — |
| Research Site | New Haven | Connecticut | — | — |
| Research Site | Washington D.C. | District of Columbia | — | — |
| Research Site | Vero Beach | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Evanston | Illinois | — | — |
| Research Site | Palos Heights | Illinois | — | — |
| Research Site | Fort Wayne | Indiana | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Des Moines | Iowa | — | — |
| Research Site | Wichita | Kansas | — | — |
| Research Site | Lexington | Kentucky | — | — |
| Research Site | Brighton | Massachusetts | — | — |
| Research Site | Hopedale | Massachusetts | — | — |
| Research Site | Lexington | Massachusetts | — | — |
| Research Site | Springfield | Massachusetts | — | — |
| Research Site | Worcester | Massachusetts | — | — |
| Research Site | Farmington Hills | Michigan | — | — |
| Research Site | Minneapolis | Minnesota | — | — |
| Research Site | Columbia | Missouri | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Henderson | Nevada | — | — |
| Research Site | Las Vegas | Nevada | — | — |
| Research Site | Lebanon | New Hampshire | — | — |
| Research Site | Albany | New York | — | — |
| Research Site | Staten Island | New York | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Dayton | Ohio | — | — |
| Research Site | Erie | Pennsylvania | — | — |
| Research Site | Hershey | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | East Providence | Rhode Island | — | — |
| Research Site | Providence | Rhode Island | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Newport News | Virginia | — | — |
| Research Site | Wien | Virginia | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 120 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00420212, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2015 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00420212 live on ClinicalTrials.gov.